Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 1573 2022-12-08 12:23:07 |
2 format corrected. + 3 word(s) 1576 2022-12-09 04:53:31 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Kanzaki, A.;  Kadoya, M.;  Katayama, S.;  Koyama, H. Physiology of Cortisol. Encyclopedia. Available online: (accessed on 16 June 2024).
Kanzaki A,  Kadoya M,  Katayama S,  Koyama H. Physiology of Cortisol. Encyclopedia. Available at: Accessed June 16, 2024.
Kanzaki, Akinori, Manabu Kadoya, Satoru Katayama, Hidenori Koyama. "Physiology of Cortisol" Encyclopedia, (accessed June 16, 2024).
Kanzaki, A.,  Kadoya, M.,  Katayama, S., & Koyama, H. (2022, December 08). Physiology of Cortisol. In Encyclopedia.
Kanzaki, Akinori, et al. "Physiology of Cortisol." Encyclopedia. Web. 08 December, 2022.
Physiology of Cortisol

Cardiac hypertrophy is a well-known condition that indicates the possibility of hypercortisolemia-inducing autonomous cortisol secretion (ACS). Because of its relationship with induction of heart failure and cardiac death, timely detection of such an alteration can lead to early diagnosis and contribute to reducing mortality. 

adrenal tumor autonomous cortisol secretion cardiac functional disorder

1. Glucocorticoid Receptor and Regulating Enzymes

The effects of bioactive cortisol, which is synthesized in the adrenal cortex, are exerted following connection to a glucocorticoid (GC) receptor (GR) or mineralocorticoid receptor (MR). GR belongs to a ligand-dependent transcription factor nuclear receptor superfamily that is comprised of three functional domains: an N-terminal transactivation domain (NTD), central DNA-binding domain (DBD), and C-terminal ligand-binding domain (LBD) [1]. Nearly all human tissues and organs express GR, which forms a multiprotein complex in cytoplasm [2]. Cortisol binding induces GR nuclear translocation with dissociation of the complex, including heat shock protein 90 [3], after which GC signaling enhances genomic and rapid non-genomic effects. MR is also a member of the ligand-dependent transcription factor nuclear receptor superfamily, showing a structural homology with GR, and induces genomic and rapid non-genomic effects in the same way as GR, though the outcome differs largely from that of GR activation and limited localization has been shown, such as cortical collecting ducts, epithelium of the large intestine and cerebrum, endothelium of blood vessels, and cardiac muscle tissue. Although both cortisol and aldosterone can function as a ligand to MR, it should be noted that cortisol has 100- to 1000-fold higher concentration in blood, and a 10- to 30-fold higher affinity to MR as compared with aldosterone. Furthermore, cortisol potentially shows both agonist and antagonist characteristics for MR [4]. However, MR transcription is seldom activated without stress or tissue injury [5][6][7], and GC was shown to function as an MR agonist in a rat heart failure model [8].
To produce an appropriate effect of cortisol and aldosterone, 11β-hydroxysteroid dehydrogenase type 1 and 2 (11β-HSD1, 2) play essential roles [9][10]. 11β-HSD1 converts inert 11-keto forms (cortisone, 11-dehydrocorticosterone) into cortisol by using the co-substrate NADPH provided by hexose-6-phophate dehydrogenase (H6PDH) [11], which results in an increase in local active cortisol concentration [12][13][14]. On the other hand, 11β-HSD2 inactivates cortisol [15][16], and has a high affinity but low capacity for NAD-dependent dehydration [17][18]. Therefore, the degree of the effect of cortisol on individual target cells is dependent on the balance of an intracellular GC-activating enzyme (11β-HSD1) and -inactivating enzyme (11β-HSD2) [19], with 11β-HSD1 inferior to 11β-HSD2 in regard to the strength of cortisol binding. For example, a suppressed effect of GC would be expected in the kidneys, where 11β-HSD2 is significantly expressed, unlike in the heart [5].

2. Physiological Role of Glucocorticoid in Rodent Cardiomyocytes

Endogenous GC contributes to maintain heart performance for regulating the life cycle of cardiomyocytes involved in growth, differentiation, metabolism, and apoptosis [20]. GC action via GR matures fetal cardiomyocytes and myofibrillar, and boosts its mitochondrial activation, by which contractile force is reinforced [21]. Narayanan et al. assessed the potential therapeutic benefits of dexamethasone treatment on myocardial function in senescent rats and demonstrated that it can reverse contractile performance by approximately two-fold caused by increased uptake of ATP-energized Ca2+ in the sarcoplasmic reticulum [22]. In addition, GC potentially inhibits cardiomyocyte apoptosis [23][24] by activating serum and glucocorticoid-responsive kinase (SGK-1), B-cell lymphoma-extra large (Bcl-xL), and growth arrest specific 2 (Gas2) [25][26]. Additionally, GR potentially protects cardiomyocytes from DNA damage and drug-induced cell death by regulating the expression of Kruppel-like factor 13 (KLF13), a major mediator of GR [27].
H6PDH activity has been identified in cardiomyocytes and fibroblasts in rats [28][29], while HSD11B1 mRNA has been observed in human hearts [30], though a physiologically normal condition restricts GC regeneration [31][32][33]. Nevertheless, 11β-HSD1 is essential for maintaining contractile force generation [31] and heart growth [34]. Interestingly, White et al. reported that cardiomyocytes lacking 11β-HSD1 in perinatal mice matured with a shortened length, though a phenotypically normal heart was successfully developed in those animals [35]. In relation to these findings, Rahman et al. presented the possibility of a reduction in left ventricular mass caused by a single nucleotide polymorphism in the HSD11B1 gene [36].

3. Harmful Effects to Cardiomyocytes by Experimental Excessive Glucocorticoid Exposure

3.1. Excessive Glucocorticoid and Cardiomyocyte Hypertrophy

Regarding the effects of excessive GC in therapeutic and pathologic conditions, abundant knowledge showing its influence with exposure to the heart has been accumulated. For example, antenatal corticosteroid therapy, known to reduce neonatal death [37], has been found to have a limited contribution to preterm birth [38], whereas it is associated with high risks of cardiovascular disease, hypertension, and type 2 diabetes in adults [39][40][41][42][43][44]. Ren et al. explored the direct effects of excessive GC on cardiomyocytes by exposing a rat embryonic cardiomyocyte cell line (H9C2) and primary cardiomyocytes to dexamethasone [27]. The results showed a significant increase in cell size along with elevated levels of expression of cardiomyocyte hypertrophic markers, such as atrial natriuretic factor (ANF), β-myosin heavy chain (β-MHC), and skeletal muscle α-actin (α-SKA) (Figure 1). Moreover, Ingenuity Pathway Analysis revealed that 58 genes were associated with cardiomyocyte hypertrophy signaling at 48 h after dexamethasone treatment. Additionally, dexamethasone was found to exhibit an anti-apoptotic effect on cardiomyocytes with exposure to tumor necrosis factor (TNF)-α with serum deprivation, while its deprivation abolished the effect of dexamethasone to elevate the expression levels of those hypertrophic maker genes, except for β-MHC. These results were diminished by addition of a GR antagonist or knock-down of GR expression, while suppression of MR activity did not have such effects, indicating the essential relationship of GR activity. Lister et al. presented findings that verified altered corticosteroid signaling in cardiomyocyte hypertrophy induced by phenylephrine (α-adrenergic receptor agonist) and phorbol ester (protein kinase C (PKC) activator), and as such signal activation is known to be involved in hypertension and diabetes [45]. Consequently, a hypertrophic response was found to accompany a significant increase in atrial natriuretic peptide mRNA (8- to 12-fold increase in both) and rDNA transcription (2-fold increase), which exhibit corticosteroid effects, and also GR and MR expression (2-fold increase) with enhanced receptor signaling. When priming with phenylephrine was performed, corticosteroids potentiated a hypertrophic response via GR, while phorbol ester-induced hypertrophy exhibited increased 11β-HSD1 expression and its reductase activity. These results indicate cross talk between corticosteroid receptor-activated pathways, and both α-adrenergic and PKC signals (Figure 1).
Figure 1. Effects of excessive glucocorticoid in cardiomyocytes and modulators of its signaling, including tissue-dependent regulation of 11β-hydroxysteroid dehydrogenase type 1. Excessive glucocorticoid (GC) enlarged the cell size of rat cardiomyocytes, with elevation of cardiomyocyte hypertrophic markers and related genes, such as atrial natriuretic factor (ANF), β-myosin heavy chain (β-MHC), and skeletal muscle α-actin (α-SKA). The glucocorticoid receptor (GR) antagonist and knockdown of GR expression attenuated that reaction, whereas suppression of mineralocorticoid receptor (MR) activity did not, indicating an essential role for GR in such a response. Phenylephrine (α-adrenergic receptor agonist) and phorbol ester (protein kinase C (PKC) activator), known to induce cardiomyocyte hypertrophy and related to hypertension and diabetes, potentiate the effects of corticosteroid and increase activated GR and MR expression. In addition, phorbol ester-induced hypertrophy exhibited increased 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) expression and reductase activity. These results indicate possible cross talk between corticosteroid receptor-activated pathways, and both α-adrenergic and PKC signals. Corticosteroid also induces an increase in intracellular sodium concentration, which is related to ischemia, heart failure, and hypertrophy. That increase was revealed to have a positive correlation with hypertrophic gene expression. Furthermore, excessive corticosterone increased the expression level of 11β-HSD1 mRNA in abdominal adipose tissue, while that was decreased in the hippocampus and liver, suggesting regulation in a tissue-dependent manner.
On the other hand, intracellular sodium kinetics in ischemia, heart failure, and hypertrophy has been considered [46][47][48][49][50]. According to a report by Katoh et al., cultured neonatal rat ventricular myocytes were treated for 24 h with corticosterone, aldosterone, and dexamethasone, and the results showed a nearly 1.5-fold increase in intracellular sodium concentration, though that occurred in a dose-dependent manner [51]. In addition, a GR antagonist reduced intracellular sodium concentration, and positive correlations between hypertrophic gene expressions and concentration were observed, findings not obtained with an MR antagonist. Additional experiments then revealed that dexamethasone upregulated the mRNA of sodium-calcium exchanger (NCX)1 and its protein, which is related to intracellular sodium homeostasis and influences calcium efflux in cardiomyocytes [49]. These findings suggest that exposure to excessive GC increases the concentration of intracellular sodium via GR, while dexamethasone treatment explains, at least in part, the direct effect of that increase, leading to cardiomyocyte hypertrophy (Figure 1).

3.2. Tissue-Specific Role of 11β-Hydroxysteroid Dehydrogenase Type 1 in Glucocorticoid Excess

When considering local regulation of GC, its association with 11β-HSD1 is another related issue. Nishiyama et al. recently confirmed the influence of 11β-HSD1 in mouse tissues showing persistent GC excess [52]. Two weeks of administration of excessive corticosterone to male mice decreased expression levels of 11β-HSD1 mRNA in the hippocampus and liver, while those were increased in abdominal adipose tissue. Furthermore, similar results were obtained with male corticotropin releasing hormone (CRH)-overexpressing transgenic mice, an animal model of CD [53][54], while performance of an adrenalectomy reversed those changes, suggesting a tissue-dependent action (Figure 1). Huang et al. also noted the role of 11β-HSD1 in cardiomyocytes [55]. Briefly, treatment of primary neonatal rat ventricular cardiomyocytes (NRCMs), which show upregulated 11β-HSD1 expression, with palmitic acid induced a significant enlargement of cell size and increased the mRNA levels of cardiomyocyte hypertrophy-specific genes, including ANF, SKA, and β-MHC, whereas either a selective inhibitor of 11β-HSD1-treated or 11β-HSD1-deficient NRCMs caused a decrease in cell size. Moreover, they also confirmed marked attenuation of 11β-HSD1-induced hypertrophy of cardiomyocytes in not only the presence of a GR antagonist (RU486), but also with the MR antagonist spironolactone, which inhibits nuclear MR translocation [56].


  1. Kumar, R.; Thompson, E.B. Gene regulation by the glucocorticoid receptor: Structure: Function relationship. J. Steroid Biochem. Mol. Biol. 2005, 94, 383–394.
  2. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889–895.
  3. Grad, I.; Picard, D. The glucocorticoid responses are shaped by molecular chaperones. Mol. Cell Endocrinol. 2007, 275, 2–12.
  4. Funder, J.W. Aldosterone and mineralocorticoid receptors: A personal reflection. Mol. Cell Endocrinol. 2012, 350, 146–150.
  5. Funder, J.; Myles, K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: In Vivo binding studies. Endocrinology 1996, 137, 5264–5268.
  6. Funder, J.W. Mineralocorticoid receptor antagonists: Emerging roles in cardiovascular medicine. Integr. Blood Press. Control 2013, 6, 129–138.
  7. Funder, J.W. Mineralocorticoid receptor activation and oxidative stress. Hypertension 2007, 50, 840–841.
  8. Mihailidou, A.S.; Le, T.Y.L.; Mardini, M.; Funder, J.W. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009, 54, 1306–1312.
  9. Seckl, J.R. 11beta-hydroxysteroid dehydrogenases: Changing glucocorticoid action. Curr. Opin. Pharmacol. 2004, 4, 597–602.
  10. Hadoke, P.W.; Iqbal, J.; Walker, B.R. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br. J. Pharmacol. 2009, 156, 689–712.
  11. Atanasov, A.G.; Nashev, L.G.; Gelman, L.; Legeza, B.; Sack, R.; Portmann, R.; Odermatt, A. Direct protein-protein interaction of 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the endoplasmic reticulum lumen. Biochim. Biophys. Acta 2008, 1783, 1536–1543.
  12. Morgan, S.A.; McCabe, E.L.; Gathercole, L.L.; Hassan-Smith, Z.K.; Larner, D.P.; Bujalska, I.J.; Stewart, P.M.; Tomlinson, J.W.; Lavery, G.G. 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proc. Natl. Acad. Sci. USA 2014, 111, E2482–E2491.
  13. Tomlinson, J.W.; Walker, E.A.; Bujalska, I.J.; Draper, N.; Lavery, G.G.; Cooper, M.S.; Hewison, M.; Stewart, P.M. 11beta-hydroxysteroid dehydrogenase type 1, a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 2004, 25, 831–866.
  14. Atanasov, A.G.; Nashev, L.G.; Schweizer, R.A.; Frick, C.; Odermatt, A. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett. 2004, 571, 129–133.
  15. Walker, B.R. Glucocorticoids and cardiovascular disease. Eur. J. Endocrinol. 2007, 157, 545–559.
  16. Yang, S.; Zhang, L. Glucocorticoids and vascular reactivity. Curr. Vasc. Pharmacol. 2004, 2, 1–12.
  17. Albiston, A.L.; Obeyesekere, V.R.; Smith, R.E.; Krozowski, Z.S. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell Endocrinol. 1994, 105, R11–R17.
  18. Brown, R.W.; Chapman, K.E.; Murad, P.; Edwards, C.R.; Seckl, J.R. Purification of 11beta-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique. Biochem. J. 1996, 313, 997–1005.
  19. Walker, B.R. Extra-adrenal regeneration of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase type 1, physiological regulator and pharmacological target for energy partitioning. Proc. Nutr. Soc. 2007, 66, 1–8.
  20. Cain, D.W.; Cidlowski, J.A. Specificity and sensitivity of glucocorticoid signaling in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 2015, 29, 545–556.
  21. Rog-Zielinska, E.A.; Thomson, A.; Kenyon, C.J.; Brownstein, D.G.; Moran, C.M.; Szumska, D.; Michailidou, Z.; Richardson, J.; Owen, E.; Watt, A.; et al. Glucocorticoid receptor is required for foetal heart maturation. Hum. Mol. Genet. 2013, 22, 3269–3282.
  22. Narayanan, N.; Yang, C.; Xu, A. Dexamethasone treatment improves sarcoplasmic reticulum function and contractile performance in aged myocardium. Mol. Cell. Biochem. 2004, 266, 31–36.
  23. Ren, R.; Cidlowski, J.A. Glucocorticoid signaling in cardiac disease. Horm. Mol. Biol. Clin. Investig. 2010, 4, 559–564.
  24. Pearl, J.M.; Nelson, D.P.; Schwartz, S.M.; Wagner, C.J.; Bauer, S.M.; Setser, E.A.; Duffy, J.Y. Glucocorticoids reduce ischemia-reperfusion-induced myocardial apoptosis in immature hearts. Ann. Thorac. Surg. 2002, 74, 830–836; discussion 836–837.
  25. Aoyama, T.; Matsui, T.; Novikov, M.; Park, J.; Hemmings, B.; Rosenzweig, A. Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. Circulation 2005, 111, 1652–1659.
  26. Ren, R.; Oakley, R.H.; Cruz-Topete, D.; Cidlowski, J.A. Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis. Endocrinology 2012, 153, 5346–5360.
  27. Cruz-Topete, D.; He, B.; Xu, X.; Cidlowski, J.A. Krüppel-like Factor 13 Is a Major Mediator of Glucocorticoid Receptor Signaling in Cardiomyocytes and Protects These Cells from DNA Damage and Death. J. Biol. Chem. 2016, 291, 19374–19386.
  28. Brereton, P.S.; van Driel, R.R.; Suhaimi, F.B.; Koyama, K.; Dilley, R.; Krozowski, Z. Light and electron microscopy localization of the 11beta-hydroxysteroid dehydrogenase type I enzyme in the rat. Endocrinology 2001, 142, 1644–1651.
  29. Gomez-Sanchez, E.P.; Romero, D.G.; de Rodriguez, A.F.; Warden, M.P.; Krozowski, Z.; Gomez-Sanchez, C.E. Hexose-6-phosphate dehydrogenase and 11beta-hydroxysteroid dehydrogenase-1 tissue distribution in the rat. Endocrinology 2008, 149, 525–533.
  30. Chai, W.; Hofland, J.; Jansen, P.M.; Garrelds, I.M.; de Vries, R.; van den Bogaerdt, A.J.; Feelders, R.A.; de Jong, F.H.; Danser, A.H. Steroidogenesis vs. steroid uptake in the heart: Do corticosteroids mediate effects via cardiac mineralocorticoid receptors? J. Hypertens. 2010, 28, 1044–1053.
  31. Lefer, A.M. Influence of corticosteroids on mechanical performance of isolated rat papillary muscles. Am. J. Physiol. 1968, 214, 518–524.
  32. Walker, B.R.; Yau, J.L.; Brett, L.P.; Seckl, J.R.; Monder, C.; Williams, B.C.; Edwards, C.R. 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: Implications for cardiovascular responses to glucocorticoids. Endocrinology 1991, 129, 3305–3312.
  33. Iqbal, J.; Andrew, R.; Cruden, N.L.; Kenyon, C.J.; Hughes, K.A.; Newby, D.E.; Hadoke, P.W.; Walker, B.R. Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist. J. Clin. Endocrinol. Metab. 2014, 99, 915–922.
  34. McSweeney, S.J.; Hadoke, P.W.; Kozak, A.M.; Small, G.R.; Khaled, H.; Walker, B.R.; Gray, G.A. Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11betaHSD1-deficient mice post-MI. Cardiovasc. Res. 2010, 88, 159–167.
  35. White, C.I.; Jansen, M.A.; McGregor, K.; Mylonas, K.J.; Richardson, R.V.; Thomson, A.; Moran, C.M.; Seckl, J.R.; Walker, B.R.; Chapman, K.E.; et al. Cardiomyocyte and Vascular Smooth Muscle-Independent 11β-Hydroxysteroid Dehydrogenase 1 Amplifies Infarct Expansion, Hypertrophy, and the Development of Heart Failure After Myocardial Infarction in Male Mice. Endocrinology 2016, 157, 346–357.
  36. Rahman, T.J.; Mayosi, B.M.; Hall, D.; Avery, P.J.; Stewart, P.M.; Connell, J.M.; Watkins, H.; Keavney, B. Common variation at the 11-β hydroxysteroid dehydrogenase type 1 gene is associated with left ventricular mass. Circ. Cardiovasc. Genet. 2011, 4, 156–162.
  37. McGoldrick, E.; Stewart, F.; Parker, R.; Dalziel, S.R. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst. Rev. 2020, 12, CD004454.
  38. Agnew, E.J.; Ivy, J.R.; Stock, S.J.; Chapman, K.E. Glucocorticoids, antenatal corticosteroid therapy and fetal heart maturation. J. Mol. Endocrinol. 2018, 61, R61–R73.
  39. Barker, D.J.; Martyn, C.N.; Osmond, C.; Hales, C.N.; Fall, C.H. Growth in utero and serum cholesterol concentrations in adult life. BMJ 1993, 307, 1524–1527.
  40. Hales, C.N.; Barker, D.J.; Clark, P.M.; Cox, L.J.; Fall, C.; Osmond, C.; Winter, P.D. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 1991, 303, 1019–1022.
  41. Law, C.M.; Shiell, A.W. Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature. J. Hypertens. 1996, 14, 935–941.
  42. Rich-Edwards, J.W.; Stampfer, M.J.; Manson, J.E.; Rosner, B.; Hankinson, S.E.; Colditz, G.A.; Willett, W.C.; Hennekens, C.H. Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976. BMJ 1997, 315, 396–400.
  43. McMillen, I.C.; Robinson, J.S. Developmental origins of the metabolic syndrome: Prediction, plasticity, and programming. Physiol. Rev. 2005, 85, 571–633.
  44. Matthews, S.G. Foetal experience: Lifelong consequences. J. Neuroendocrinol. 2007, 19, 73–74.
  45. Lister, K.; Autelitano, D.J.; Jenkins, A.; Hannan, R.D.; Sheppard, K.E. Cross talk between corticosteroids and alpha-adrenergic signaling augments cardiomyocyte hypertrophy: A possible role for SGK1. Cardiovasc. Res. 2006, 70, 555–565.
  46. Despa, S.; Islam, M.A.; Weber, C.R.; Pogwizd, S.M.; Bers, D.M. Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 2002, 105, 2543–2548.
  47. Baartscheer, A.; Schumacher, C.A.; Belterman, C.N.; Coronel, R.; Fiolet, J.W. i and the driving force of the Na+/Ca2+-exchanger in heart failure. Cardiovasc. Res. 2003, 57, 986–995.
  48. Pogwizd, S.M.; Sipido, K.R.; Verdonck, F.; Bers, D.M. Intracellular Na in animal models of hypertrophy and heart failure: Contractile function and arrhythmogenesis. Cardiovasc. Res. 2003, 57, 887–896.
  49. Pieske, B.; Houser, S.R. i handling in the failing human heart. Cardiovasc. Res. 2003, 57, 874–886.
  50. Murphy, E.; Eisner, D.A. Regulation of intracellular and mitochondrial sodium in health and disease. Circ. Res. 2009, 104, 292–303.
  51. Katoh, D.; Hongo, K.; Ito, K.; Yoshino, T.; Kayama, Y.; Kawai, M.; Date, T.; Yoshimura, M. Corticosteroids increase intracellular free sodium ion concentration via glucocorticoid receptor pathway in cultured neonatal rat cardiomyocytes. Int. J. Cardiol. Heart Vessel. 2014, 3, 49–356.
  52. Nishiyama, M.; Iwasaki, Y.; Nakayama, S.; Okazaki, M.; Taguchi, T.; Tsuda, M.; Makino, S.; Fujimoto, S.; Terada, Y. Tissue-specific regulation of 11β hydroxysteroid dehydrogenase type-1 mRNA expressions in Cushing’s syndrome mouse model. Steroids 2022, 183, 109021.
  53. Stenzel-Poore, M.P.; Cameron, V.A.; Vaughan, J.; Sawchenko, P.E.; Vale, W. Development of Cushing’s syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 1992, 130, 3378–3386.
  54. Nakayama, S.; Nishiyama, M.; Iwasaki, Y.; Shinahara, M.; Okada, Y.; Tsuda, M.; Okazaki, M.; Tsugita, M.; Taguchi, T.; Makino, S.; et al. Corticotropin-releasing hormone (CRH) transgenic mice display hyperphagia with increased Agouti-related protein mRNA in the hypothalamic arcuate nucleus. Endocr. J. 2011, 58, 279–286.
  55. Huang, M.; Liu, J.; Sheng, Y.; Lv, Y.; Yu, J.; Qi, H.; Di, W.; Lv, S.; Zhou, S.; Ding, G. 11β-hydroxysteroid dehydrogenase type 1 inhibitor attenuates high-fat diet induced cardiomyopathy. J. Mol. Cell. Cardiol. 2018, 125, 106–116.
  56. Lavall, D.; Schuster, P.; Jacobs, N.; Kazakov, A.; Böhm, M.; Laufs, U. Rac1 GTPase regulates 11β hydroxysteroid dehydrogenase type 2 and fibrotic remodeling. J. Biol. Chem. 2017, 292, 7542–7553.
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , ,
View Times: 335
Revisions: 2 times (View History)
Update Date: 09 Dec 2022
Video Production Service